Drug details

Brenzavvy (bexagliflozin tablets)

type of Antidiabetics, SGLT2 Inhibitors

Brenzavvy (bexagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The following drugs are related to Brenzavvy, either as a replacement or used together:

• Amaryl Tablets (glimepiride)
• Basaglar (basaglar insulin glargine subcutaneous injection)
• Bydureon (exenatide)
• Bydureon Bcise (exenatide extended-release injectable suspension)
• Invokana (canagliflozin tablets)
• Jardiance (empagliflozin tablets)
• Steglatro (ertugliflozin tablets for oral use)
• Glumetza (metformin hcl)
• Tresiba (insulin degludec injection)
• Januvia (sitagliptin phosphate)
• Tradjenta (linagliptin)
• Victoza (liraglutide [rdna] injection)
• Mounjaro (tirzepatide injection)
• Onglyza (saxagliptin tablets)
• Ozempic (semaglutide injection)
• Prandin (repaglinide)
• Rybelsus (semaglutide tablets)